On the Radio: Sean Kirk Discusses Emergent's Role in Supporting COVID-19 Vaccine Candidates

By Catherine Hanley on Jun 26, 2020 1:40:26 PM

Washington Wonk-FM's Stacy Lyn recently spoke to Emergent Executive Vice President, Manufacturing and Technical Operations Sean Kirk regarding the company's recent partnerships and ongoing efforts to support COVID-19 vaccine candidates.  

Listen to the full interview here. 

Topics: news
4 min read

Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability

By Catherine Hanley on Jun 18, 2020 9:15:00 AM

  • Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing facility to increase campus footprint and build out advanced therapy capability
  • Advanced therapy CDMO drug substance manufacturing services expected to be available beginning in 2023
  • Expansion will enable molecule-to-market CDMO services in viral vector and gene therapy utilizing Emergent’s integrated network with development services and drug product manufacturing to be offered out of its Gaithersburg and Rockville, Maryland facilities, respectively   

GAITHERSBURG, Md., June 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that it will further strengthen its contract development and manufacturing (CDMO) capabilities by expanding into viral vector and gene therapy. The company will invest $75 million in its Canton, Massachusetts facility, which is focused on the development and manufacturing of drug substance for live viral vaccines, including the company’s smallpox vaccine.

Topics: news
1 min read

Editorial: Good Manufacturing Practices: Challenges with Compliance

By Catherine Hanley on Jun 17, 2020 9:36:31 AM

Dino Muzzin, Senior Vice President, Manufacturing Operations at Emergent, recently contributed to an article in BioPharm International titled, Good Manufacturing Practices: Challenges with Compliance.

In this article, Muzzin and other industry experts discuss obstacles, best practices for compliance, and where further guidance may be needed to fill the gaps in GMPs.

Topics: editorials
5 min read

Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate

By Catherine Hanley on Jun 11, 2020 3:45:36 PM

  • Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidate
  • Agreement valued at approximately $87 million

GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it will deploy its molecule-to-market contract development and manufacturing (CDMO) services to support the manufacturing of AstraZeneca’s vaccine candidate for COVID-19, AZD1222, a viral vector-based, weakened version of adenovirus containing the genetic material of SARS-CoV-2 spike protein, developed by Oxford University’s Jenner institute working with the Oxford Vaccine Group.

Topics: COVID-19
1 min read

BPI Theater Presentation at Bio Digital

By Catherine Hanley on Jun 5, 2020 9:00:00 AM

Topic: Solutions for Rapid Development and Manufacturing Responses to COVID-19 and Other Public Health Threats

Speaker: Richard W. Welch, Ph.D., Vice President Development Services, Emergent BioSolutions

Date: OnDemand Presentation

Topics: events

Emergent Participating in Virtual Partnering at BIO Digital, June 8 - 12

By Catherine Hanley on Jun 3, 2020 4:36:33 PM

Emergent BioSolutions will be participating in Bio Digital the week of June 8 - 12. 

Wherever you are in your journey, Emergent offers solutions from a respected CDMO with extensive experience working with governments, regulatory agencies, and biopharma companies of all sizes.

Request a Meeting
Topics: events
1 min read

Emergent Continues to Expand Role in Support of Development and Manufacturing of COVID-19 Vaccines

By Catherine Hanley on Jun 2, 2020 9:30:00 AM

Emergent BioSolutions recently announced that it has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines.

Topics: COVID-19
6 min read

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

By Catherine Hanley on Jun 1, 2020 6:45:00 AM

  • Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021  
  • Emergent will provide molecule-to-market CDMO services and commit manufacturing capacity, valued at approximately $542.7 million, paving the way for pharmaceutical and biotechnology innovators to advance COVID-19 programs
  • Task order also includes approximately $85.5 million for expansion of Emergent’s viral and non-viral CDMO drug product fill/finish capacity

GAITHERSBURG, Md., June 01, 2020 (GLOBE NEWSWIRE)  - Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines.

Topics: COVID-19
1 min read

May 4th Webinar: Rapid Readiness for Pandemic Response

By Catherine Hanley on Apr 26, 2020 5:09:37 PM

Watch our latest webinar on the topic of how drug developers can maximize capacity, capabilities and expertise for pandemic response. This presentation is Part 2 in a Coronavirus Virtual Series brought to you by FiercePharma with featured speaker Sean Kirk, EVP Manufacturing & Technical Operations.

Topics: COVID-19 webinar
4 min read

Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19

By Catherine Hanley on Apr 26, 2020 5:03:01 PM

GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE)

Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby Emergent will deploy its contract development and manufacturing (CDMO) services to support the manufacturing of Johnson & Johnson’s lead vaccine candidate for COVID-19 that leverages the AdVac® and PER.C6® technologies from the Janssen Pharmaceutical Companies of Johnson & Johnson.

Topics: COVID-19 J&J

Featured